Everything below concerns Tesamorelin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-17. Numbers and descriptions here follow the published literature rather than marketing material.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
| Property | Value | Notes |
|---|---|---|
| Routine purity assay | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Identity confirmation | Liquid chromatography–mass spectrometry | Mass shift reveals modification or truncation |
| Typical purity specification | Greater than 95 percent | Reported as main-peak area percentage |
| Long-term storage | Minus 20 degrees Celsius or colder | Sealed, protected from light |
| Principal degradation routes | Oxidation, deamidation, aggregation | Monitored individually during stability studies |
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Depending on the concentration of the sample, the magnetic field of the spectrometer, and the type of experiment, a single multidimensional nuclear magnetic resonance experiment on a protein sample may take hours or even several days to obtain suitable signal-to-noise ratio through signal averaging, and to allow for sufficient evolution of magnetization transfer through the various dimensions of the experiment. Other things being equal, higher-dimensional experiments will take longer than lower-dimensional experiments. Typically, the first experiment to be measured with an isotope-labelled protein is a 2D heteronuclear single quantum correlation (HSQC) spectrum, where "heteronuclear" refers to nuclei other than 1H. In theory, the heteronuclear single quantum correlation has one peak for each H bound to a heteronucleus. Thus, in the 15N-HSQC, with a 15N labelled protein, one signal is expected for each nitrogen atom in the back bone, with the exception of proline, which has no amide-hydrogen due to the cyclic nature of its backbone. Additional 15N-HSQC signals are contributed by each residue with a nitrogen-hydrogen bond in its side chain (W, N, Q, R, H, K). The 15N-HSQC is often referred to as the fingerprint of a protein because each protein has a unique pattern of signal positions. Analysis of the 15N-HSQC allows researchers to evaluate whether the expected number of peaks is present and thus to identify possible problems due to multiple conformations or sample heterogeneity.
There are several vulval restorative surgeries known as genitoplasties, and some of these are also used as cosmetic surgery procedures. Different cultures have held different views of the vulva. Some ancient religions and societies have worshipped the vulva and revered the female as a goddess. Major traditions in Hinduism continue this. In Western societies, there has been a largely negative attitude, typified by the Latinate medical terminology pudenda membra, meaning 'parts to be ashamed of'. There has been an artistic reaction to this in various attempts to bring about a more positive and natural outlook.
=== Genetics === The observation of high rates of autoimmune disorders in families with a history of Sjögren's disease is linked with a genetic predisposition to the disease. Studies on the polymorphisms of human leukocyte antigen (HLA)-DR and HLA-DQ gene regions in Sjögren's patients show differential susceptibility to the disease as the result of different types of the resulting autoantibody production.
Transurethral resection of the prostate (TURP) replaced radical prostatectomy for symptomatic relief of obstruction in the middle of the 20th century because it could better preserve penile erectile function. Radical retropubic prostatectomy was developed in 1983 by Patrick Walsh. In 1941, Charles B. Huggins published studies in which he used estrogen to oppose testosterone production in men with metastatic prostate cancer. This discovery of "chemical castration" won Huggins the 1966 Nobel Prize in Physiology or Medicine. The role of the gonadotropin-releasing hormone (GnRH) in reproduction was determined by Andrzej W. Schally and Roger Guillemin, who both won the 1977 Nobel Prize in Physiology or Medicine for this work. GnRH receptor agonists, such as leuprorelin and goserelin, were subsequently developed and used to treat prostate cancer. Radiation therapy for prostate cancer was first developed in the early 20th century and initially consisted of intraprostatic radium implants. External beam radiotherapy became more popular as stronger X-ray radiation sources became available in the middle of the 20th century. Brachytherapy with implanted seeds (for prostate cancer) was first described in 1983. Systemic chemotherapy for prostate cancer was first studied in the 1970s. The initial regimen of cyclophosphamide and 5-fluorouracil was quickly joined by multiple regimens using a host of other systemic chemotherapy drugs.
Sources: en.wikipedia.org
Mamadou Diallo Sory - Former minister of Justice Maman Sambo Sidikou - former Ambassador Nigerien to the United States, United Nations secretary-general's special representative for the Democratic Republic of the Congo and head of the U.N. peacekeeping mission there, MONUSCO, high representative of the African Union for Mali and the Sahel. Abdoulaye Diori Kadidiatou Ly - jurist, former president of the Constitutional Court of Niger. Abdou Sidikou - former minister of foreign affairs, Niger. Yaou Sangaré Bakary - former ambassador to China, Minister of Foreign Affairs. Bouli Ali Diallo - academic and activist, Niger. Achta Djibrine Sy former Minister of Commerce and Industry, Chad. Banata Tchale Sow - economist, former chief of staff, Chad. Hindou Oumarou Ibrahim- environmental activist and geographer. Coordinator Association of Peul Women and Autochthonous People of Chad (AFPAT) and Co-director Pavilion of World Indigenous People, Chad Mariam Boni Diallo - first female foreign minister, Benin Republic. Ali Darassa – leader of the Central African rebel group, the Union for Peace in the Central African Republic (UPC) a self-defense force. Al-Amin Abu-Manga, linguist and professor at the University of Khartoum Ali Mohamed Issah Salou Jules Hamidou Habib Habibou Hassan Diallo
Biologic debridement has the added benefit of being bactericidal since larvae will ingest bacteria as well as devitalized tissue. Despite the safety and effectiveness of this method, its applications are often limited due to patient's negative feelings towards larvae which are commonly associated with poor hygiene and perishable food.
== Operations == As of 2025, KEZAD Group’s infrastructure and services span 12 economic zones across Abu Dhabi, Al Ain and Al Dhafra Region, as well as an industrial and logistics zone in East Port Said, Egypt, covering a total area of 570 sq km. KEZAD Group’s platform supports over 2,300 businesses across 17 economic sectors, including logistics, automotive, food and beverages, pharmaceuticals, metals, chemicals, packaging, and clean energy industries.
Sources: en.wikipedia.org
=== Thermoregulation === Fish are cold-blooded, and in general their body temperature is the same as that of their surroundings. They gain and lose heat through their skin, and regulate their circulation in response to changes in water temperature by increasing or reducing the blood flow to the gills. Metabolic heat generated in the muscles or gut is quickly dissipated through the gills, with blood being diverted away from the gills during exposure to cold. Because of their relative inability to control their blood temperature, most teleosts can only survive in a small range of water temperatures. Teleost species that inhabit colder waters have a higher proportion of unsaturated fatty acids in brain cell membranes compared to fish from warmer waters, which allows them to maintain appropriate membrane fluidity in the environments in which they live. When cold acclimated, teleost fish show physiological changes in skeletal muscle that include increased mitochondrial and capillary density. This reduces diffusion distances and aids in the production of aerobic ATP, which helps to compensate for the drop in metabolic rate associated with colder temperatures. Tuna and other fast-swimming ocean-going fish maintain their muscles at higher temperatures than their environment for efficient locomotion. Tuna achieve muscle temperatures 11 °C (19 °F) or even higher above the surroundings by having a counterflow system in which the metabolic heat produced by the muscles and present in the venous blood, pre-warms the arterial blood before it reaches the muscles.
==== Financial inclusion ==== Digital agriculture technologies can expand farmers' access to credit, insurance, and bank accounts for a number of reasons. First, digital technology helps alleviate the information asymmetry that exists between farmers and financial institutions. When lenders decide a farmer's credit ceiling or insurance premium, they are usually uncertain about what risks the farmer presents. Digital technology reduces the costs of verifying farmers' expected riskiness. The Kenyan company M-Shwari uses customers' phone and mobile money records to assess creditworthiness. Organizations like FarmDrive and Apollo Agriculture incorporate satellite imagery, weather forecasts, and remote sensor data when calculating farmers' loan eligibility. Drone imagery can confirm a farmer's physical assets or land use and Asset tracking using RFID technology allows stakeholders to monitor livestock, making it easier for insurers to understand farmers' riskiness. In all instances, low-cost digital verification reduces lenders' uncertainty: the questions "will this farmer repay the loan?" and "what risks does this farmer face?" become clearer. Second, digital technology facilitates trust between farmers and financial institutions. A range of tools create trust, including real-time digital communication platforms and blockchain/distributed ledger technology/smart contracts. In Senegal, a digitalized, supply-chain-tracking system allows farmers to collateralize their rice to obtain the credit necessary for planting.
== Human proteins containing laminin domains == Laminin domain I: all laminin alpha chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5) Laminin domain II: all laminin alpha chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5) Laminin B (domain IV): all laminin alpha chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5), gamma chains (LAMC1, LAMC2, LAMC3), and perlecan (HSPG2) Laminin EGF-like (domains III and V): all laminin chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5, LAMB1, LAMB2, LAMB3, LAMB4, LAMC1, LAMC2, LAMC3), attractins (ATRN, ATRNL1), cadherin EGF LAG seven-pass G-type receptors (CELSR1, CELSR2, CELSR3), cysteine-rich with EGF-like domain proteins (CRELD1, CRELD2), multiple EGF-like domain proteins (MEGF6, MEGF8, MEGF9, MEGF10, PEAR1), most netrins (NTN1, NTN3, NTN4, NTNG1, NTNG2), mucins 3A and 3B (MUC3A, MUC3B), class F scavenger receptors (SCARF1, SCARF2), stabilins (STAB1, STAB2), agrin (AGRIN), angiopoietin-1 receptor (TEK), perlecan (HSPG2), tenascin N (TNN), and usherin (USH2A).
Agüero insisted that she "never harmed any person, much less a baby." On 30 April, the prosecution formally requested the sentence of life imprisonment for Agüero, accusing her of deliberately injecting the babies with potassium and insulin to gain the attention of the medical staff when she attempted to resuscitate them. On 8 May, Agüero's defense lawyer gave the final statement before the court, saying that Agüero is innocent and that she was framed by "the power" (in reference to the provincial government) to blame her for the negligence of providing expired medications and concealing systematic malpractice among the hospital's medical personnel. Agüero's defense counsel later concluded his statement formally requesting the jury to acquit Agüero of all charges. In their final impact statement before the court, the mothers of the murdered babies accused Agüero and her lawyers of falsely implying that they "cried for money" (in relation to civil trials against the provincial government) and also demanded that Agüero be sentenced to life in prison. Agüero gave her final statement on 12 June, with the verdict expected for 18 June. Agüero denied the charges again, and in a tense moment in court, accused the mothers of the babies of being "scripted", prompting emotional reactions from the gallery. Agüero, in part, said:
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the standard technique for purity and content. Mass spectrometry provides orthogonal confirmation of identity. The two are normally used together rather than in isolation.
Removing water slows hydrolysis and limits the mobility that drives aggregation. A dry powder is also less hospitable to microbial growth. These factors make cold storage of the solid form more forgiving than storage of a reconstituted solution.
Methionine oxidation, asparagine and glutamine deamidation, and non-covalent or covalent aggregation are the main routes reported for peptides of this class. Each is tracked as a separate impurity. Their relative abundance depends on formulation and storage history.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.